Cochrane · systematic review · CD012584
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non‐cardiac surgery
Lewis, SR, Pritchard, MW, Schofield‐Robinson, OJ, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
AnaesthesiaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 1 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non‐cardiac surgery
Population: adults undergoing non‐cardiac surgery (including abdominal, urological, orthopaedic, and gynaecological surgery)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (at longest Continuation vs discontinuation of antiplatelet therapy | RR 1.21 [0.34, 4.27] | 5 studies · 659 participants | Low Downgraded: imprecision |
All‐cause mortality (up to 30 days) Continuation vs discontinuation of antiplatelet therapy | RR 1.21 [0.34, 4.27] | 4 studies · 616 participants | Low Downgraded: imprecision |
Blood loss requiring transfusion of blood products (intraoperatively and postoperatively) Continuation vs discontinuation of antiplatelet therapy | RR 1.37 [0.83, 2.26] | 4 studies · 368 participants | Moderate Downgraded: imprecision |
Blood loss requiring further surgery (intraoperatively and postoperatively) Continuation vs discontinuation of antiplatelet therapy | RR 1.54 [0.31, 7.58] | 4 studies · 368 participants | Low Downgraded: imprecision |
Ischaemic events: peripheral thrombosis, cerebral myocardial infarction (within 30 days of surgery) Continuation vs discontinuation of antiplatelet therapy | RR 0.67 [0.25, 1.77] | 4 studies · 616 participants | Low Downgraded: imprecision, inconsistency |